<DOC>
	<DOC>NCT01996735</DOC>
	<brief_summary>Preclinical studies have shown that the P2Y12 receptor antagonist ticagrelor can increase the extracellular concentration of the endogenous nucleoside adenosine by inhibiting the cellular uptake of adenosine via the equilibrative nucleoside transporter (ENT). This mechanism can contribute to the beneficial effects and to the side effects (dyspnea) of ticagrelor in patients with an acute myocardial infarction. In the current research proposal, we aim to investigate whether ticagrelor increases adenosine receptor stimulation in humans in vivo by ENT inhibition.</brief_summary>
	<brief_title>Ticagrelor and Adenosine</brief_title>
	<detailed_description />
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Male sex Age 1840 years Healthy Written informed consent Smoking Hypertension (Blood pressure &gt;140 mmHg and/or &gt;90 mmHg SBP/DBP) Diabetes Mellitus (fasting glucose &gt; 7.0 mmol/L or random &gt; 11.0 mmol/L) History of any cardiovascular disease History of chronic obstructive pulmonary disease (COPD) or asthma Bleeding tendency Concomitant use of medication Renal dysfunction (MDRD &lt; 60 ml/min) Liver enzyme abnormalities (ALAT &gt; twice upper limit of normality) Thrombocytopenia (&lt;150*109/ml) Second/third degree AVblock on electrocardiography</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Endothelial function</keyword>
	<keyword>Adenosine receptor stimulation</keyword>
</DOC>